Pharmacokinetic (PK) Bioequivalence and Pharmacodynamics (PD) of Julphar Insulin 30/70 and Huminsulin® Profil III

Diabetes Mellitus Clinical Trial

Official title:

Single-center, Randomized, Double-blind, 2-treatment, 2-period Crossover Trial in Healthy Subjects to Demonstrate PK Bioequivalence and to Compare the PD Properties of Julphar Insulin 30/70 and Huminsulin® Profil III

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02631928
• Other study ID #: INSULCT002
• Secondary ID: 2015-003993-34
• Status: Completed
• Phase: Phase 1
• First received: November 25, 2015
• Last updated: August 1, 2016
• Start date: February 2016
• Est. completion date: June 2016

Study information

• Verified date: August 2016
• Source: Julphar Gulf Pharmaceutical Industries
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical Devices
• Study type: Interventional

Clinical Trial Summary

This study in healthy volunteers aims to demonstrate similar PK and PD properties of the new human biphasic insulin, Julphar Insulin 30/70 and an already approved reference insulin, Huminsulin® Profil III. All participants will receive both study treatments on two separate dosing days.

Description:

Daily injections of insulin is a necessity for many patients with diabetes mellitus in order to treat hyperglycaemia. Julphar Insulin 30/70 and Humininsulin® Profil III are both biphasic insulins, i.e. consist of a mixture of short-acting soluble insulin and intermediate-acting isophane insulin. The new insulin, Julphar Insulin 30/70, is biosimilar to Huminsulin® Profil III. Demonstration of similar absorption (PK) and effects (PD) are necessary to achieve market approval of Julphar Insulin 30/70.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 73
• Est. completion date: June 2016
• Est. primary completion date: June 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the subject).

• Healthy male subject.

• Age between 18 and 55 years, both inclusive.

• Body Mass Index (BMI) between 18.5 and 28.0 kg/m^2, both inclusive.

• Fasting plasma glucose concentration <= 100 mg/dL.

Exclusion Criteria:

• Known or suspected hypersensitivity to IMPs or related products.

• Previous participation in this trial. Participation is defined as randomised.

• Receipt of any medicinal product in clinical development within 3 months before screening.

• Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator.

• Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness as judged by the Investigator.

• Surgery within 12 weeks before the start of the study or blood donation of more than 500 mL (or considerable blood loss) or plasma donation within the last 3 months.

• Increased risk of thrombosis, e.g., subjects with a history of deep leg vein thrombosis or family history of deep leg vein thrombosis, as judged by the Investigator.

• Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator.

• Supine blood pressure (BP) at screening (after resting for 5 minutes in a supine position) outside the range of 90 to 140 mmHg for systolic BP or 50 to 90 mmHg for diastolic BP (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine pulse < 50 beats per minute.

• Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.

• Any disease or condition that, in the opinion of the Investigator, would represent an unacceptable risk for the subject's safety.

• Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen.

• History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.

• Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol.

• Any medication (prescription and non-prescription drugs) within 14 days before first trial drug administration and/or anticoagulant therapy, with the exception of stable treatment with thyroid hormones, paracetamol and ibuprofen for occasional use to treat pain.

• Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 330 mL of beer, one glass of wine of 120 mL, or 40 mL spirits).

• A positive result in the alcohol and/or urine drug screen at the screening visit.

• Smoker (defined as a subject who is smoking more than 5 cigarettes or the equivalent per day) who is not able or willing to refrain from smoking and use of nicotine substitute products 1 day before and during the inpatient period.

• Subject with mental incapacity or language barriers precluding adequate understanding or cooperation or who, in the opinion of the Investigator, should not participate in the trial.

• Potentially noncompliant or uncooperative during the trial, as judged by the Investigator.

Study Design

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus

Intervention

Drug:
• human biphasic insulin
investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
• human biphasic insulin, reference
marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin

Locations

Country	Name	City	State
Germany	Profil Institut für Stoffwechselforschung GmbH	Neuss

Sponsors (2)

Lead Sponsor	Collaborator
Julphar Gulf Pharmaceutical Industries	Profil Institut für Stoffwechselforschung GmbH

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PK: AUCins.0-24, harea under the serum insulin concentration curve from 0-24 hours		24 hours	No
Primary	PK: Cins.max, maximum observed insulin concentration	24 hours	24 hours	No
Secondary	PK: AUCins.0-6h, AUCins.0-12, areas under the serum insulin concentration curve in the indicated time intervals		12 hours	No
Secondary	PK: AUCins.0-8, area under the serum insulin concentration-time curve from 0 hours to infinity		24 hours	No
Secondary	PK: tmax, time to maximum observed serum insulin concentration		24 hours	No
Secondary	PK: t½, terminal serum elimination half-life calculated as t½=ln2/?z		24 hours	No
Secondary	PK: ?z, terminal elimination rate constant of insulin		24 hours	No
Secondary	PD: AUCGIR.0h-last, area under the glucose infusion rate curve from 0 hours until the end of clamp		24 hours	No
Secondary	PD: GIRmax, maximum observed glucose infusion rate		24 hours	No
Secondary	PD: AUCGIR.0-6h, AUCGIR.0-12h, areas under the glucose infusion rate curve in the indicated time-intervals		12 hours	No
Secondary	PD: tGIR.max, time to maximum glucose infusion rate		24 hours	No
Secondary	PD: Onset of action, time from trial product administration until blood glucose concentration has decreased at least 5 mg/dL from baseline	baseline is defined as the mean of blood glucose levels from -6, -4, and -2 minutes before trial product administration as measured by the glucose clamp device	24 hours	No
Secondary	Adverse events	Through study completion, approx.up to approx. 39 days for each subject and up to 6 month for total study duration..	from the first trial drug administration until the final examination	Yes
Secondary	Local tolerability findings	at the injection site. Through study completion,; The local tolerability at the injection site will be evaluated by means of the following assessments: spontaneous pain; pain on palpation; itching; erythema; oedema; induration/infiltration; other Each of these assessments will be reported on a scale of 0 (none), 1 (mild), 2 (moderate) and 3 (severe). The evaluation and the actual time of the assessment will be recorded.	dosing period, approx.up to 39 days for each subject	Yes
Secondary	Laboratory safety parameters	Including haematology, biochemistry and coagulation including serology (only at screening) parameters. Through study completion,	from screening until final examination, approx.up to 60 days for each subject	Yes
Secondary	Physical examination findings	Through study completion,	from screening until final examination, approx.up to 60 days for each subject	Yes
Secondary	Changes in vital signs	Through study completion,	from screening until final examination, approx.up to 39 days for each subject	Yes
Secondary	Changes in Electrocardiogram recordings	Through study completion,	from screening until final examination, approx.up to 60 days for each subject	Yes